---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124653"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:57:53.477496+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cogent Q3 net loss $70.6M; PEAK trial enrolls 413 patients, top-line data in 2025

## Summary
- Net loss $70.6M in Q3 2024 vs $55.4M in Q3 2023; cash $345.5M sufficient into late 2026.
- Phase 3 PEAK GIST trial completed enrollment (413 patients); IDMC recommended continuation after futility analysis.
- Top-line results expected from SUMMIT (2H 2025), APEX (mid-2025), PEAK (end of 2025).
- Phase 1 trial initiated for CGT-4859 FGFR2 inhibitor; preclinical data for KRAS and PI3K inhibitors presented.
- Inducement grants of options to purchase 132,350 shares to three new employees.

## SEC filing metadata
- accession: 0000950170-24-124653
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000095017024124653/0000950170-24-124653-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000095017024124653/cogt-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124653
- JSON: https://secwatch.observer/filing/0000950170-24-124653.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124653.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.